Nektar Therapeutics (NKTR) Retained Earnings (2010 - 2026)

Nektar Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$3.8 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 9756997.44% year-over-year to -$3.8 billion in Q1 2026; TTM through Mar 2026 was -$3.8 billion, a 9756997.44% decrease from a year earlier, with the FY2025 full-year figure at $17000.0, down 72.13% from the prior year.
• Retained Earnings fell to -$3.8 billion in Q1 2026 per NKTR's latest filing, from $17000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $80000.0 in Q4 2023 and bottomed at -$3.8 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$3.2 billion (2022), against an average of -$1.9 billion.
• Across the five-year window, Retained Earnings jumped 100.0% in 2023 and plunged 9756997.44% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$3.2 billion in 2022, then jumped by 100.0% to $80000.0 in 2023, then fell by 23.75% to $61000.0 in 2024, then sank by 72.13% to $17000.0 in 2025, then plunged by 22383570.59% to -$3.8 billion in 2026.
• Per Business Quant, the three latest NKTR Retained Earnings figures stand at -$3.8 billion (Q1 2026), $17000.0 (Q4 2025), and -$3.7 billion (Q3 2025).